IS8213A - Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu - Google Patents

Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu

Info

Publication number
IS8213A
IS8213A IS8213A IS8213A IS8213A IS 8213 A IS8213 A IS 8213A IS 8213 A IS8213 A IS 8213A IS 8213 A IS8213 A IS 8213A IS 8213 A IS8213 A IS 8213A
Authority
IS
Iceland
Prior art keywords
polypeptide
immune response
response against
protective immune
nettle
Prior art date
Application number
IS8213A
Other languages
English (en)
Icelandic (is)
Inventor
S. Anderson Annaliesa
Ute Jansen Kathrin
Kelly Rosemarie
D. Schultz Loren
L. Montgomery Donna
L. Mcclements William
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS8213A publication Critical patent/IS8213A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IS8213A 2003-07-24 2005-12-30 Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu IS8213A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
IS8213A true IS8213A (is) 2005-12-30

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8213A IS8213A (is) 2003-07-24 2005-12-30 Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu

Country Status (23)

Country Link
US (2) US20060177462A1 (enExample)
EP (1) EP1651166B8 (enExample)
JP (1) JP2007502101A (enExample)
KR (1) KR20060065643A (enExample)
AT (1) ATE457737T1 (enExample)
AU (1) AU2004258979B2 (enExample)
BR (1) BRPI0412799A (enExample)
CA (1) CA2532370A1 (enExample)
CY (1) CY1110028T1 (enExample)
DE (1) DE602004025579D1 (enExample)
DK (1) DK1651166T3 (enExample)
ES (1) ES2342778T3 (enExample)
HR (1) HRP20100240T1 (enExample)
IL (1) IL173253A0 (enExample)
IS (1) IS8213A (enExample)
MX (1) MXPA06000854A (enExample)
NO (1) NO20060898L (enExample)
NZ (2) NZ544542A (enExample)
PL (1) PL1651166T3 (enExample)
PT (1) PT1651166E (enExample)
RU (1) RU2337108C2 (enExample)
SI (1) SI1651166T1 (enExample)
WO (1) WO2005009379A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2555342A1 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2581746A1 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario Staphylococcus aureus isd protein-based anti-infectives
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
EP1982185A4 (en) * 2006-01-27 2010-04-28 Merck Sharp & Dohme ON S. AUREUS ORF0657N OBJECTIVE ANTIGEN-BINDING PROTEINS
WO2008140632A2 (en) 2007-01-24 2008-11-20 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus epidermidis
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
US20100166772A1 (en) * 2007-05-31 2010-07-01 Anderson Annaliesa S ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CN102292104A (zh) 2008-11-26 2011-12-21 默沙东公司 用于诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
SMT202000246T1 (it) 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
CA2758490C (en) * 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (en) * 2010-03-12 2014-01-08 Univ Pennsylvania METHOD FOR PREVENTING AND TREATING THE COLONIZATION OF STAPHYLOCOCCUS AUREUS AND THEIR INFECTIOUS DISEASES AND DISEASES
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
US8747858B2 (en) 2010-07-13 2014-06-10 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
KR20140066212A (ko) 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP2320233A1 (en) * 2001-06-15 2011-05-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
US7456276B2 (en) * 2001-11-12 2008-11-25 Novo Nordisk A/S Peptide purification by means of metal ion affinity chromatography
WO2003053462A2 (en) * 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
IL173253A0 (en) 2006-06-11
EP1651166A2 (en) 2006-05-03
AU2004258979B2 (en) 2007-12-06
ATE457737T1 (de) 2010-03-15
MXPA06000854A (es) 2006-03-30
ES2342778T3 (es) 2010-07-14
RU2337108C2 (ru) 2008-10-27
NZ570750A (en) 2009-12-24
DE602004025579D1 (de) 2010-04-01
HRP20100240T1 (hr) 2010-09-30
EP1651166A4 (en) 2008-03-05
PT1651166E (pt) 2010-04-23
AU2004258979A1 (en) 2005-02-03
CA2532370A1 (en) 2005-02-03
CY1110028T1 (el) 2015-01-14
NO20060898L (no) 2006-04-24
WO2005009379A3 (en) 2006-11-30
US20100247561A1 (en) 2010-09-30
EP1651166B8 (en) 2010-05-19
US20060177462A1 (en) 2006-08-10
NZ544542A (en) 2009-01-31
DK1651166T3 (da) 2010-05-31
SI1651166T1 (sl) 2010-06-30
EP1651166B1 (en) 2010-02-17
BRPI0412799A (pt) 2006-09-26
JP2007502101A (ja) 2007-02-08
KR20060065643A (ko) 2006-06-14
PL1651166T3 (pl) 2010-08-31
RU2006105498A (ru) 2006-09-10
WO2005009379A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
IS8213A (is) Fjölpeptíð til að kalla fram verndandi ónæmissvörun gegn gullinni klasahnettlu
WO2005079315A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
ATE417595T1 (de) Keratin-bindende polypeptide
ATE419359T1 (de) Cdc27-homologe aus arabidopsis thaliana
DE69936105D1 (de) Menschliche tslp nukleinsäuren und polypeptide
NO20063026L (no) Antistoffer
PT1151103E (pt) Nac1 - um gene de plantas codificador de um factor de transcricao envolvido no desenvolvimento de cotiledones e raizes laterais
WO2005115113A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A3 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
DK2076532T3 (da) Cytokinderivater
ATE481420T1 (de) Il-21-derivate
WO2007001361A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
PH12013502021A1 (en) Platelet aggregation inhibitor composition
ATE452970T1 (de) N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen
ATE513848T1 (de) Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität
WO2007018482A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
ATE305941T1 (de) Impfstoff
FR2874025B1 (fr) Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila
WO2006121664A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
EP1536010A4 (en) PREVENTIVE / REMEDY AGAINST CANCER
NZ606260A (en) Novel polypeptides involved in immune response
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide